Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the...

Related Keywords

Spain ,Vienna ,Wien ,Austria ,United States ,American ,Yusri Elsayed ,Bernadette King ,Paula Rodr ,Satu Glawe ,Janssen Biotech Inc ,European Hematology Association ,Cancer Research Institute ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Department Of Hematology ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Other Administration Reactions ,Drug Administration ,European Commission ,Exchange Commission ,Companies Of Johnson ,Amgen Inc ,European Medicines Agency ,Johnson ,Hematology Association ,Annual Congress ,Universidad De Navarra ,Vice President ,Disease Area Leader ,Hematologic Malignancies ,Janssen Research ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Biologics License Application ,Janssen Biotech ,Mayo Stage ,Patients With ,With Determination ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Refractory Multiple Myeloma ,Updated Phase ,Combination With Daratumumab Subcutaneously ,Versus Daratumumab ,Participants With Relapsed ,Accessed June ,Natl Acad Sci United ,Clin Cancer ,Cell Therapy ,Accessed December ,Serious Conditions ,Statistics About Multiple Myeloma ,The Janssen Pharmaceutical Companies Of Johnson Amp ,